Pendulum Therapeutics Announces Strategic Partnership and $10M Investment From Global Nutrition Science Leader, Fonterra

The strategic investment signals growing global interest in microbiome science and paves the way for future commercialization of microbiome products

SAN FRANCISCO–(BUSINESS WIRE)–Pendulum Therapeutics, the biotech company pioneering the next frontier of metabolic health through its microbiome-targeted products, announced today a strategic partnership with New Zealand dairy nutrition company Fonterra. Fonterra will invest $10 million into the growth-stage company to co-develop and commercialize next-generation microbiome products.

The digestive health products market is exploding, sized at $51 billion globally (Source: Grandview). The strategic partnership leverages Fonterra’s innovation, manufacturing expertise, and long-standing leadership in global markets, alongside Pendulum’s deep science-backed innovation, microbiome expertise and category leadership in the U.S. probiotic market. The investment accelerates Pendulum’s ability to bring forward solutions that help people address gut microbiome deficiencies, which affect 40% of people globally (Gastroenterology).

“This investment from Fonterra, a $14 billion global company, signals that gut health is increasingly being recognized as an important factor in whole-body health and wellness,” said Colleen Cutclfife, Ph.D., CEO and Co-founder of Pendulum Therapeutics. “Pendulum’s scientists are conducting cutting-edge microbiome research and developing products that have a meaningful and measurable impact on metabolic health for millions of people. This strategic partnership with Fonterra enables us to tap into their deep-rooted manufacturing expertise and established global presence to bring a new wave of microbiome products to market.”

The $10 million investment from Fonterra will come from their newly formed nutrition science venture arm, provisionally named Nutrition Science Solutions (NSS). NSS will incubate, invest in and scale ventures in the nutrition science field, and operate as a standalone business within Fonterra with its own board and CEO. The investment will also designate Fonterra as a minority shareholder in the San Francisco-based biotech company.

As part of the strategic partnership, NSS and Pendulum will work together to co-develop and commercialize next-generation products that are scientifically formulated to make a measurable impact on people’s gut microbiome health, helping consumers overcome certain health conditions like immunity, mental health, cognitive health, and aging.

“Nutrition science is a segment of the global health and wellness category that goes beyond everyday lifestyle and wellness products, and we’re excited to tap into it more deeply through our partnership with Pendulum,” said Miles Hurrell, CEO of Fonterra.

“Our shared objective to bring proven, high impact health products to the world led us to partner with and invest in Pendulum. We’re confident that together we can deliver health solutions that make measurable improvements to people’s health around the world.”

Pendulum products are available online at Amazon, Pendulum Therapeutics website, Dr. Mark Hyman Store, Walmart Marketplace, Fullscript and The Cleveland Clinic online pharmacy.

View hi-res Imagery HERE.

For more information, please contact [email protected].

About Pendulum:

Pendulum Therapeutics is disrupting the probiotics industry by pioneering the next frontier to restore metabolic health. The biotech company develops microbiome-targeted products that have the power and efficacy of a pharmaceutical with the safety and accessibility of a probiotic to lower blood sugar spikes, reduce A1C levels and manage metabolic health. Colleen Cutcliffe, CEO and co-founder, earned her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and leads a diverse team of scientists with deep microbiology, biochemistry, computational and clinical expertise. In a published clinical trial, Pendulum’s flagship product, Pendulum Glucose Control, a medical probiotic, demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in individuals with T2D taking metformin. Pendulum is armed with 22 patents and 63 pending. Pendulum has raised $111 million to date with investments from Meritech Capital, Sequoia Capital, actress Halle Berry, True Ventures, Khosla Ventures, AME Cloud Ventures, and Mayo Clinic among others. The company was founded in 2012 and is headquartered in San Francisco.

Contacts

Geena Dimaano

[email protected]